SCHEMBL2159790

SCHEMBL2159790

CCCCC[C@H]1CC[C@H](N)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.50
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
GNAI3 P08754 2/20 0.44
GNAO1 P09471 2/20 0.44
GNAI1 P63096 2/20 0.44
PKM P14618 1/20 0.41
SPHK1 Q9NYA1 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
EPHX1 P07099 1/20 0.40
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TP53 P04637 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LSS P48449 2/20 0.38
MAPT P10636 1/20 0.37
SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2159788 1.00 CYP1A2 (0.50) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL17592459 1.00 CYP1A2 (0.50) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL2404044 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL2406734 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL2406519 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL25015820 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL2405113 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL25015819 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL2405787 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3
SCHEMBL24920262 0.98 CYP1A2 (0.48) CYP1A2HTTLMNAMAPK1GNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305859-A1 An Anticonvulsant Compound ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2017-10-26 US claimed
EP-3191088-A1 AN ANTICONVULSANT COMPOUND Royal Holloway And Bedford New College (GB) 2017-07-19 EP claimed
WO-2016038379-A1 AN ANTICONVULSANT COMPOUND ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2016-03-17 WO claimed
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. 2023-02-09 US disclosed
US-10301263-B2 Anticonvulsant compound ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2019-05-28 US disclosed
US-20170305859-A1 An Anticonvulsant Compound ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2017-10-26 US disclosed
EP-3191088-A1 AN ANTICONVULSANT COMPOUND Royal Holloway And Bedford New College (GB) 2017-07-19 EP disclosed
WO-2016038379-A1 AN ANTICONVULSANT COMPOUND ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2016-03-17 WO disclosed
US-8450726-B2 Articles containing coatings of amic acid salts EASTMAN KODAK COMPANY (US) 2013-05-28 US disclosed
US-8431433-B2 Methods of providing semiconductor layers from amic acid salts EASTMAN KODAK COMPANY (US) 2013-04-30 US disclosed
US-8404892-B2 Aromatic amic acid salts and compositions EASTMAN KODAK COMPANY (US) 2013-03-26 US disclosed
US-8212243-B2 Organic semiconducting compositions and N-type semiconductor devices EASTMAN KODAK COMPANY (US) 2012-07-03 US disclosed
US-8212243-B2 Organic semiconducting compositions and N-type semiconductor devices EASTMAN KODAK COMPANY (US) 2012-07-03 US disclosed
US-20110294257-A1 METHODS OF PROVIDING SEMICONDUCTOR LAYERS FROM AMIC ACID SALTS KODAK AMERICAS LTD. 2011-12-01 US disclosed
US-20110295010-A1 AROMATIC AMIC ACID SALTS AND COMPOSITIONS FPC INC. 2011-12-01 US disclosed
US-20110180784-A1 ORGANIC SEMICONDUCTING COMPOSITIONS AND N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
US-20110183462-A1 METHOD OF MAKING N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
US-20110180784-A1 ORGANIC SEMICONDUCTING COMPOSITIONS AND N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
US-20110183462-A1 METHOD OF MAKING N-TYPE SEMICONDUCTOR DEVICES BANK OF AMERICA, N.A., AS AGENT 2011-07-28 US disclosed
WO-2011090953-A1 ORGANIC SEMICONDUCTING COMPOSITIONS AND N-TYPE SEMICONDUCTOR DEVICES EASTMAN KODAK COMPANY (US) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295010-A1 AROMATIC AMIC ACID SALTS AND COMPOSITIONS DDC, MYOC, TNNC1 CYP1A2 679/4885HTT 1568/4885LMNA 290/4885
US-20170305859-A1 An Anticonvulsant Compound PSEN2, BACE2, APP CYP1A2 279/4885HTT 453/4885LMNA 2224/4885
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF MMP7, MATR3, SPINT2 CYP1A2 1458/4885HTT 1483/4885LMNA 1207/4885
US-10301263-B2 Anticonvulsant compound PSEN2, BACE2, APP CYP1A2 230/4885HTT 514/4885LMNA 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.